June 30, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) in the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from April 1 to June 30, 2016.
| ||Type of Security(1)||Number of Shares/ADSs|
|Dominic Blakemore||Shares||150|| |
|Olivier Bohuon||Shares||134|| |
|William Burns ||Shares||190|| |
|Gail Fosler||ADSs||13|| |
|Dr. Steven Gillis ||ADSs||61|| |
|Dr. David Ginsburg||ADSs||57|| |
|Susan Kilsby ||ADSs||189|| |
|Sara Mathew ||ADSs||54|| |
|Anne Minto ||Shares||179|| |
|Albert Stroucken||ADSs||17|| |
(1) One ADS is equal to three Shares.
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £44.6306 per Share and $182.7877 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Senior Assistant Company Secretary
For further information please contact:
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.